Preoperative weight loss program for hepatocellular carcinoma patients with high body mass index in hepatectomy.

Authors

null

Yu Saito

Department of Surgery, Tokushima University, Tokushima, Japan

Yu Saito , Yuji Morine , Shinichiro Yamada , Hiroki Teraoku , Tetsuya Ikemoto , Mitsuo Shimada

Organizations

Department of Surgery, Tokushima University, Tokushima, Japan

Research Funding

No funding sources reported

Background: This study aimed to investigate the usefulness of a weight-loss program (WLP) in patients with a high body mass index (BMI) prior to liver resection (Hx) for hepatocellular carcinoma (HCC). Methods: Among 445 patients with HCC who underwent initial Hx between 2000 and 2020, 19 with a high BMI (≥25.0) were enrolled in our WLP since 2014. For calorie restriction, the amount of energy consumed was calculated as the standard body weight (SBW) kg × 20–25 kcal/day. Protein mass was calculated as SBW kg × 1.0–1.2 g/day to maintain skeletal muscle mass. Patients also performed both aerobic and resistance exercises. The before-and-after changes were compared, and the effect of WLP on the short- and long-term results was investigated. Results: The average length of WLP was 21 days, and weight loss was successfully achieved in all patients. Body fat mass was reduced during the program, while skeletal muscle mass was maintained. WLP led to improvements in liver function and fibrotic markers, without tumor progression. There were no postoperative complications (≥Clavien–Dindo [CD] III). A retrospective comparison of postoperative outcomes revealed that those in the WLP group showed a significantly shorter operation time and improved postoperative morbidity rate (≥CD III) with decreased postoperative hospital stay. There were no significant differences in long-term prognosis based on participation in the WLP. Conclusions: WLP with multidisciplinary intervention improved short-term outcomes after Hx in patients with HCC and a high BMI.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Other

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr 565)

DOI

10.1200/JCO.2024.42.3_suppl.565

Abstract #

565

Poster Bd #

G13

Abstract Disclosures

Similar Abstracts

Abstract

2023 ASCO Annual Meeting

The impact of high body mass index on hepatocellular carcinoma in viral hepatitis and cirrhosis.

First Author: Moonho Kim

Abstract

2024 ASCO Genitourinary Cancers Symposium

Association of body-mass index (BMI) with age, PSA, and survival in metastatic prostate cancer.

First Author: Martin W. Schoen